corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published during the years 1970 to 1979

There are 379 items in the Healthy Skepticism Library that were published during the years 1970 to 1979.

Page 1 of 4 pages  1 2 3 >  Last ›

HSL3024
Chapman S.
Prescription drug advertising
Medical Journal of Australia 1979 Nov 29; 66:700

HSL3023
Ferris JD.
Prescription drug advertising
Medical Journal of Australia 1979 Nov 17; 66:550

HSL2990
Feinstein AR, Horwitz RI.
Avoiding conflicts of interest in drug research.
N Engl J Med 1979 Nov 1; 301:(18):1009

HSL2993
Greenberg BG.
Avoiding conflicts of interest in drug research.
N Engl J Med 1979 Nov 1; 301:(18):1008

HSL3004
Relman AS.
Who reviews the ads?
N Engl J Med 1979 Nov 1; 301:(18):999

HSL3022
Tannock IF.
Responsibility in advertising: an oncologist's view
New England Journal of Medicine 1979 Nov 1; 300:1004

HSL2987
Chapman S.
Advertising and psychotropic drugs: the place of myth in ideological reproduction.
Soc Sci Med [Med Psychol Med Sociol] 1979 Nov; 13A:(6):751-64

HSL3021
Kleinman G.
The physician’s drug adoption process re: product risk
Medical Marketing & Media 1979 Nov; 14:46, 48-50

HSL16701
Wolfe S
The Conflict Between Individual Freedom and Social Control: Saccharin and Food Additives
Ann N.Y. Acad. Sci 1979 Nov; 329:42‑245

HSL16702
Wolfe S
The Dichotomy Between Theory and Practice in Risk/Benefit Analysis
Ann N.Y. Acad. Sci 1979 Nov; 329:274‑276

HSL8546
Leclerc Chevalier D
Ottawa report: Bureau of Drug Quality Assessment
Canadian Pharmaceutical Journal 1979 Oct; 112:293-294

HSL8550
Fink JL.
Marketing in a generic environment: pharmacist's view
Medical Marketing and Media 1979 Oct; 14:40, 42, 44, 46

HSL3017
Dukes MN.
Identifying the medical consultants of pharmaceutical companies.
Lancet 1979 Sep 29; 2:(8144):696

HSL2991
Fitzgerald FT.
Detail men in white coats.
N Engl J Med 1979 Sep 20; 301:(12):668

HSL3016
Burley DM.
Identifying the medical consultants of pharmaceutical companies.
Lancet 1979 Aug 18; 2:(8138):354

HSL3002
Petsonk EL.
Conflicts of interest in drug research.
N Engl J Med 1979 Aug 9; 301:(6):335

HSL8551
Barbieri J.
New prescription drug labeling requirement
US Pharmacist 1979 Aug; 4:19-21

HSL3015
Lunde PK, Herxheimer A.
Identifying the medical consultants of pharmaceutical companies.
Lancet 1979 Jul 28; 2:(8135):197

HSL3008
Solomon F, Mendelson WB.
Sleeping pills.
N Engl J Med 1979 Jul 26; 301:(4):214-5

HSL3014
Kelly NR.
Prescription drug advertising
Medical Journal of Australia 1979 Jul 14; 66:40

HSL3006
Schwartz H.
Junk mail.
N Engl J Med 1979 Jul 5; 301:(1):53

HSL3007
Snead OC.
Junk mail.
N Engl J Med 1979 Jul 5; 301:(1):53

HSL3010
Stock SL.
Junk mail.
N Engl J Med 1979 Jul 5; 301:(1):53

HSL8547
Najman JM, Siskind V, Bain C.
Prescription drug advertising: medical journal practices under different types of control.
Med J Aust 1979 May 19; 1:(10):420-4

HSL2988
Christensen DB, Wertheimer AI.
Sources of information and influence on new drug prescribing among physicians in an HMO.
Soc Sci Med 1979 May; 13A:(3):313-22

HSL2980
Binns TB, Smith A.
Medical representatives.
Br Med J 1979 Apr 28; 1:(6171):1134-5

HSL3005
Relman AS.
The sulindac story: what is medical news?
N Engl J Med 1979 Mar 29; 300:(13):733-4

HSL3011
Thompson EL.
Sexual bias in drug advertisements.
Soc Sci Med 1979 Mar; 13A:(2):187-91

HSL8541
Independents: holding their own
National Association of Retail Druggists Journal 1979 Mar; 101:23-24

HSL3012
Wasner C, Kotzin B.
Sulindac "public relations" deplored.
N Engl J Med 1979 Feb 15; 300:(7):373

HSL1878
Kaplan NM.
Sounding Boards.The support of continuing medical education by pharmaceutical companies
N Engl J Med 1979 Jan 25; 300:(4):194-6

HSL3009
Solomon SD, Grimmett BL, Maurer KH, Levin NW.
Complaint about promotion of new anti-arthritic drug.
N Engl J Med 1979 Jan 25; 300:(4):203

HSL2996
Lion JR, Regan BL, Taylor RJ, Kutzer DJ.
Psychiatrists' opinions of psychotropic drug advertisements.
Soc Sci Med [Med Psychol Med Sociol] 1979 Jan; 13A:(1):123-5

HSL2989
Editor .
Publicity about sulindac [Editor's reply]
New England Journal of Medicine 1979; 300:(13):735

HSL2992
Frisof KB, Parnicky K.
The burden of junk mail
New England Journal of Medicine 1979; 300:865-866

HSL2994
Hughes R, Brewin R.
The tranquilizing of America: pill popping and the American way of life
1979;

HSL2995
Kaplan NM.
The support of continuing medical education by pharmaceutical companies
New England Journal of Medicine 1979; 300:194-196

HSL2997
Lobo F.
Monopolistic structures and industrial analysis in Spain: the case of the pharmaceutical industry.
Int J Health Serv 1979; 9:(4):663-82

HSL2998
Mallace AH.
Publicity about sulindac [2nd of 4 letters]
New England Journal of Medicine 1979; 300:(13):734

HSL2999
Martin RW.
Diuretic equivalence of frusemide preparations
New Zealand Medical Journal 1979; 90:209

HSL3000
Miller DR.
Publicity about sulindac [3rd of 4 letters]
New England Journal of Medicine 1979; 300:(13):735

HSL3001
Miller JA, Waller R.
Health care advertising: consumer vs. physician attitudes
Journal of Advertising 1979; 8:(4):20-29

HSL3003
Pyeritz RE.
The burden of junk mail
New England Journal of Medicine 1979; 301:866

HSL9077
Medawar C.
Insult or Injury
London: Social Audit 1979
http://www.amazon.co.uk/Insult-Injury-Charles-Medawar/dp/0950339210/ref=sr_1_6/026-0515181-7375631?ie=UTF8&s=books&qid=1175254557&sr=1-6

HSL2958
Green B.
The politics of psychoactive drug use in old age.
Gerontologist 1978 Dec; 18:(6):525-30

HSL2964
Kunin CM.
Clinical investigators and the pharmaceutical industry.
Ann Intern Med 1978 Nov; 89:(5):

HSL8559
Kunin CM.
Problem of antibiotic usage. Definitions, causes, and proposed solutions
Ann Intern Med. 1978 Nov; 89:(5):802-5.

HSL2963
Kalb CC.
Psychological motivations in physician prescribing habits.
Med Mark Media 1978 Oct; 13:(10):43-5,

HSL8549
Kalb CL.
Psychological motivations in physician prescribing habits
Medical Marketing and Media 1978 Oct; 13:43-45, 49, 50, 52, 54, 55

HSL8553
What companies do pharmacists now select when filling Rx's for 16 generic drugs? Part 2
Pharmacy Times 1978 Oct; 44:45-49

HSL2314
Dajda R.
Drug advertising and prescribing.
J R Coll Gen Pract 1978 Sep; 28:(194):538-41
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=739456&query_hl=23

HSL2973
Talley CR.
Hospitals defend formulary decisions against industry attacks.
Am J Hosp Pharm 1978 Sep; 35:(9):1154-5

HSL8552
What companies do pharmacists now select when filling Rx's for 16 generic drugs? Part 1
Pharmacy Times 1978 Sep; 44:54-58

HSL16700
Wolfe S
Now, Let the Victim Beware
Mother Jones 1978 Sep14-18

HSL2972
Shearer SW, Gagnon JP, Eckel FM.
Community, hospital and clinical pharmacists and drug information centers as physician drug information sources.
Am J Hosp Pharm 1978 Aug; 35:(8):909-14

HSL2976
Walton H.
A case for medical journal advertising
Medical Marketing & Media 1978 Aug; 13:37-43

HSL8560
Gardner VR, Fulda TR.
Drug insurance and cost containment: an evaluation of where we're going.
Hosp Formul 1978 Jun; 13:(6):460-1,

HSL3013
Paine TF.
Advertising (quantified)
JAMA1979 May 25;241(21):2264 1979 May 25; 241:(21):2264

HSL8548
Braucher CL.
Pharmacy ethics-professional idealism and reality
American Journal of Pharmaceutical Education 1978 May; 42:141-143

HSL2975
Peretz SM.
Medical journal advertising as currently viewed by the pharmaceutical industry.
J R Soc Med 1978 Apr; 71:(4):282-4

HSL8561
Annual survey report-research and development activities ethical pharmaceutical industry, 1976 with forecast for 1977
Medical Marketing and Media 1978 Mar; 13:17-18, 20-24, 26-30

HSL2957
Medical journals and advertising
N Z Med J. 1978 Feb 22; 87:(606):139

HSL8555
Dolan M.
Target practice at FDA: talking back to the regulators
American Pharmacy 1978 Feb; 36-40

HSL2971
Roustan PT.
The pharmaceutical manufacturers representative.
Drug Inf J 1978 Jan-Mar; 12:(1):15-9

HSL8563
Garton WM.
Pharmaceutical industry in Canada: its environment and performance
Canadian Pharmaceutical Journal 1978 Jan; 111:6-7

HSL2959
Harrell GD, Lindsay CM.
Pharmaceutical marketing
1978; 69-90

HSL2960
Holmes JD.
Drug advertisements information
New Zealand Medical Journal 1978; 87:226

HSL2961
Holst H.
Unsolicited advertising
Canadian Medical Association Journal 1978; 118:24

HSL2962
Hornbrook MC.
Market structure and advertising in the US pharmaceutical industry
Medical Care 1978; 16:90-109

HSL2965
Lall S, Bibile S.
The political economy of controlling transnationals: the pharmaceutical industry in Sri Lanka, 1972-1976.
Int J Health Serv 1978; 8:(2):299-328

HSL2966
Larson LN, Smith MC.
An analysis of the effects of “fair balance” in prescription drug advertising
Medical Marketing & Media 1978; 13:(6):26-27, 31

HSL2967
Martin RW.
Drug advertisements
New Zealand Medical Journal 1978; 87:295

HSL2968
Phillips JS.
Drug advertisements
New Zealand Medical Journal 1978; 87:102-103

HSL2969
Rheinstein PH, Hugstad PS.
The regulation of prescription drug advertising
1978; 407-416

HSL2970
Rice DI.
Misleading advertising of drug products
Canadian Family Physician 1978; 24:101-102

HSL2974
Yudkin JS.
Provision of medicines in a developing country
Lancet 1978; 1:810-812

HSL2977
Eastman M.
The day the detail man talked
American Pharmacy 1978; 18:(11):592

HSL2978
Ahmad S, Sheikh AI, Meeran MK.
Publicity about sulindac [1st of 4 letters]
New England Journal of Medicine 1978; 300:(13):734

HSL2979
Bell W.
Accredited pharmaceutical manufacturers representatives
Canadian Medical Association Journal 1978; 120:1327

HSL2986
Blakeslee A.
Publicity about sulindac [4th of 4 letters]
New England Journal of Medicine 1978; 300:(13):735

HSL8556
Presentation of price lists
Krankenhaus Apotheke 1978; 28:(2):15-16

HSL8558
Haines BA.
Worldwide regulations and legislation; their effects on pharmaceutical product development
Drug Development and Industrial Pharmacy 1978; 4:(1):1-30

HSL19891
Phillips PJ
Kill or Cure: Lotions, Potions, Characters and Quacks of Early Australia Richmond, Vic: Greenhouse Publishing 19780
http://www.blaqbooks.com.au/index.php?route=product/product&path=49&product_id=1599

HSL8562
Wheeler V.
MSD unveils first computer controlled drug plant
Drug Cosmet Ind 1977 Dec; 121:48-50

HSL2932
Holmes JD.
Prescribing information in drug advertisements.
N Z Med J 1977 Nov 23; 86:(600):467-9

HSL2921
Dixon RB.
The current status of guidelines for clinical research from the viewpoint of the pharmaceutical industry.
J Clin Pharmacol 1977 Nov-Dec; 17:(11-12):691-6
http://jcp.sagepub.com/cgi/reprint/17/11/691

HSL8565
Smith MC.
Drug product advertising and prescribing: a review of the evidence.
Am J Hosp Pharm 1977 Nov; 34:(11):1208-24

HSL2920
Da Sylva NP.
Drug information sources for the practicing physician.
Drug Inf J 1977 Oct-Dec; 11:(4):235-7

HSL2935
Marchand CR.
Physician attitudes toward sources of drug information.
Drug Inf J 1977 Oct-Dec; 11:(4):225-6

HSL2937
Meadows RJ.
Drug information: the pharmaceutical manufacturer's viewpoint and involvement.
Drug Inf J 1977 Oct-Dec; 11:(4):221-4

HSL2943
Stahl E.
The medical copywriter in the pharmaceutical industry: an uphill climb after a downhill slide.
Drug Inf J 1977 Oct-Dec; 11:(4):215-7

HSL2929
Holland AE.
Representatives and advertisements as sources of information.
Postgrad Med J 1977 Sep; 53:(623):559-61

HSL2933
Kenny EC.
Information centres in the pharmaceutical industry--the prime source of drug information.
Postgrad Med J 1977 Sep; 53:(623):562-5

HSL2955
Brown P.
Pharmaceutical promotion in Europe - regulations and restrictions
Medical Marketing & Media 1977 Sep; 12:(9):27, 30, 32, 34, 36, 38

HSL2956
Smith MC, Strecker P, Hair JF.
Sex appeals in prescription drug advertising
Medical Marketing & Media 1977 Sep; 12:(9):64, 66-70

HSL2936
Martin RW.
Drug costs.
N Z Med J 1977 Aug 24; 86:(594):202

HSL2938
Russell WL, Dahlin PA.
Industry's interest.
Drug Intell Clin Pharm 1977 Aug; 11:(8):493-4

HSL2954
Mergener M.
Detailmen: Their pharmaceutical knowledge and continuing education
Medical Marketing & Media 1977 Aug; 12:(8):26, 28-31

HSL2930
Holmes JD.
Drug costs.
N Z Med J 1977 Jul 27; 86:(592):108-9

HSL2953
Kunin CM.
Blunder drug for pneumonia.
N Engl J Med 1977 Jul 14; 297:(2):113-4

Page 1 of 4 pages  1 2 3 >  Last ›

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.







...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.